Kethandapatti Balaji

Seeing and Sensing Cancer: PSMA-PET and ctDNA for Smarter Monitoring of Metastatic Prostate Cancer

Inclusion of POSLUMA PET Imaging Improves Specificity of MRI in Diagnosis of Prostate Cancer

An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of Lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and Lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway Inhibitors in patients with PSMA PET scan positive Castration-Resistant Prostate Cancer

Clinical Validation of ClarityDX Prostate as a reflex test to PSA to refine the prediction of clinically-significant prostate cancer

An Expanded Access Program for the non-invasive detection of clear cell renal cell carcinoma (ccRCC) in patients with renal masses utilizing 89Zirconium-labelled girentuximab (89Zr-DFO-girentuximab)#

A Prospective, Multi-Center, Single-Blind, Randomized, Active-Controlled- Study of BD ORC Original Absorbable Hemostat Compared with Surgicel® Original Absorbable Hemostat

A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination with Durvalumab in Adult BCG-naïve, High-risk Non–Muscle-Invasive Bladder Cancer Participants (PATAPSCO)

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer

A Phase 2, Randomized, Open-label, Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration -resistant prostrate cancer (TAMARACK)

Establishment of an Inclusive Cancer Care Research Equity (iCCaRE) for Black Men Consortium

“Protocol Title: A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib Maintenance in mCRPC Patients with Homologous Recombination Repair Gene Alterations after Docetaxel Treatment” (the “Study”)

A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

CTOA

Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN Registry)

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer

COMBINATORIAL INHIBITION OF MYC IN PROSTATE CANCER

Combinatorial Inhibition of MYC in Prostate Cancer

The collection of whole blood and other human bio-fluid specimens from subjects clinically diagnosed with cancer and/or other related disease.

ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

Tracking Origins of Prostate Cancer: An Innovative In Vivo Modeling

MT 2A Phosphorylation by PKC Mu/PKD Influences Chemosensitivity to Cisplatin in Prostate Cancer